Clinical Trial Update: Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update assesses alternate dosing regimens of epoetin alfa (PROCRIT) in cancer patients with chemotherapy-induced anemia. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Anemia

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, Chemotherapy | Phase 2 | Status: COMPLETED